Teva Pharmaceutical Industries Ltd. $TEVA Shares Bought by Harel Insurance Investments & Financial Services Ltd.

Harel Insurance Investments & Financial Services Ltd. grew its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 19.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 44,951,773 shares of the company’s stock after buying an additional 7,255,083 shares during the period. Teva Pharmaceutical Industries accounts for about 12.1% of Harel Insurance Investments & Financial Services Ltd.’s holdings, making the stock its biggest holding. Harel Insurance Investments & Financial Services Ltd.’s holdings in Teva Pharmaceutical Industries were worth $1,402,945,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in TEVA. AQR Capital Management LLC increased its stake in shares of Teva Pharmaceutical Industries by 24.6% in the first quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock valued at $368,000 after buying an additional 4,732 shares during the period. Focus Partners Wealth boosted its position in shares of Teva Pharmaceutical Industries by 4.5% during the 1st quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after purchasing an additional 1,739 shares in the last quarter. Franklin Resources Inc. bought a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at about $255,000. Flow Traders U.S. LLC bought a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at about $238,000. Finally, Cerity Partners LLC boosted its position in shares of Teva Pharmaceutical Industries by 2.9% during the 2nd quarter. Cerity Partners LLC now owns 45,837 shares of the company’s stock valued at $768,000 after purchasing an additional 1,291 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Buying and Selling

In other news, CEO Richard D. Francis sold 442,935 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $32.36, for a total value of $14,333,376.60. Following the transaction, the chief executive officer owned 642,099 shares in the company, valued at $20,778,323.64. This trade represents a 40.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Eliyahu Sharon Kalif sold 345,810 shares of the firm’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $33.64, for a total value of $11,633,048.40. Following the completion of the transaction, the executive vice president owned 57,478 shares in the company, valued at $1,933,559.92. This represents a 85.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 1,086,339 shares of company stock valued at $35,852,268. 0.54% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Stock Up 1.5%

Shares of NYSE:TEVA opened at $35.86 on Wednesday. The business’s 50 day simple moving average is $31.19 and its two-hundred day simple moving average is $29.57. The firm has a market cap of $41.24 billion, a P/E ratio of 26.97, a PEG ratio of 3.42 and a beta of 0.86. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01. Teva Pharmaceutical Industries Ltd. has a 52-week low of $14.99 and a 52-week high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. The business had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. As a group, research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.49 EPS for the current fiscal year.

Key Stories Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Analysts are lifting Teva’s fair value and reframing the investment case (higher fair value to $40.09), signaling improved Street confidence in R&D, biosimilars and capital allocation — a clear near‑term catalyst for demand. Read More.
• Positive Sentiment: Multiple brokerages have raised price targets recently (reports include increases up to $45), and Piper Sandler reiterated an Overweight — these upgrades and higher targets support buying interest and headline momentum. Read More.
• Positive Sentiment: Teva will present at the BofA Securities Health Care Conference on May 12 (EVP of R&D to speak). Management comments on pipeline, R&D progress or commercial execution there could produce a directional move. Read More.
• Neutral Sentiment: Street estimates remain constructive but not unanimous — consensus near‑term EPS estimates sit around ~$2.5–2.6 for the year, which frames valuation (current P/E in the mid‑20s). This keeps upside tied to execution and guidance.
• Negative Sentiment: Insider selling: EVP Christine Fox sold 21,258 shares (~25% reduction of her stake) at an average price ~$35.31; such insider dispositions can be read as a negative signal or simply routine liquidity. Read More.
• Negative Sentiment: Large insider sale: Director/executive Mark Sabag sold 144,180 shares (~64% reduction) at ~ $34.99 — a sizable disposition that may temper sentiment from analyst upgrades. Read More.

Analyst Ratings Changes

TEVA has been the topic of several research analyst reports. Scotiabank upped their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research report on Thursday, January 29th. Jefferies Financial Group upped their target price on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. The Goldman Sachs Group upped their target price on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Wall Street Zen lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “hold” rating in a research report on Saturday. Finally, JPMorgan Chase & Co. upped their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $41.56.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.